| ID Source | ID |
|---|---|
| PubMed CID | 11673921 |
| CHEMBL ID | 377219 |
| SCHEMBL ID | 5815398 |
| MeSH ID | M0514679 |
| Synonym |
|---|
| 3-[[5-(2,3-dichlorophenyl)tetrazol-1-yl]methyl]pyridine |
| CHEMBL377219 , |
| a-438079 |
| a438079 , |
| AKOS016035814 |
| bdbm50410955 |
| a 438079 |
| HY-15488 |
| CS-1293 |
| NCGC00347906-01 |
| 3-((5-(2,3-dichlorophenyl)-1h-tetrazol-1-yl)methyl)pyridine |
| 3-{[5-(2,3-dichlorophenyl)-1h-1,2,3,4-tetrazol-1-yl]methyl}pyridine |
| gtpl4118 |
| MMPAULQSJLVKHP-UHFFFAOYSA-N |
| 3-{[5-(2,3-dichlorophenyl)-1h-tetraazol-1-yl]methyl}pyridine |
| SCHEMBL5815398 |
| 3-[[5-(2,3-dichlorophenyl)-1h-tetrazol-1-yl]methyl]pyridine |
| NCGC00347906-04 |
| 3-[5-(2,3-dichloro-phenyl)-tetrazol-1-ylmethyl]-pyridine |
| Q27074072 |
| HMS3748O07 |
| MS-24422 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|---|---|---|---|
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 4.2534 | AID1645841 |
| G | Vesicular stomatitis virus | Potency | 21.3174 | AID1645842 |
| Interferon beta | Homo sapiens (human) | Potency | 21.3174 | AID1645842 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 21.3174 | AID1645842 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 21.3174 | AID1645842 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 21.3174 | AID1645842 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|---|---|---|---|
| Transient receptor potential cation channel subfamily A member 1 | Homo sapiens (human) | IC50 | 0.0590 | AID1913032; AID1913329 |
| P2X purinoceptor 7 | Rattus norvegicus (Norway rat) | IC50 | 0.4321 | AID1831763; AID266264; AID321350; AID423046; AID597637 |
| P2X purinoceptor 7 | Rattus norvegicus (Norway rat) | Ki | 0.2000 | AID1831767 |
| P2X purinoceptor 7 | Homo sapiens (human) | IC50 | 0.4830 | AID1358119; AID1831762; AID266262; AID321349; AID423041; AID597636 |
| P2X purinoceptor 7 | Homo sapiens (human) | Ki | 0.0680 | AID1831766 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | Ki | 0.5055 | AID1915176 |
| P2X purinoceptor 7 | Mus musculus (house mouse) | IC50 | 2.9000 | AID1831764 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 ISSN: 2472-5560 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173ISSN: 1872-9096 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173ISSN: 1872-9096 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | 2022 | The Journal of biological chemistry, 08, Volume: 298, Issue:8 ISSN: 1083-351X | |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173ISSN: 1872-9096 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 ISSN: 2211-1247 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1831767 | Displacement of [3H]-A-804598 from rat P2X7 receptor expressed in HEK293 cell membrane by in vitro binding assay | 2021 | Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8 ISSN: 1520-4804 | Synthesis and Characterization of the Novel Rodent-Active and CNS-Penetrant P2X7 Receptor Antagonist Lu AF27139. |
| AID423041 | Antagonist activity at P2X7 receptor in human THP1 cells assessed as inhibition of BzATP-induced ethidium uptake | 2009 | Journal of medicinal chemistry, May-28, Volume: 52, Issue:10 ISSN: 1520-4804 | Antagonists of the P2X(7) receptor. From lead identification to drug development. |
| AID760096 | Antagonist activity at P2X7 in Sprague-Dawley rat synaptosome assessed as inhibition of BzATP-induced [3H]D-aspartate efflux preincubated at 10 uM for 8 mins by liquid scintillation counting in absence of extracellular Ca2+ | 2013 | ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8 ISSN: 1948-5875 | Flow Synthesis and Biological Studies of an Analgesic Adamantane Derivative That Inhibits P2X7-Evoked Glutamate Release. |
| AID266268 | Oral bioavailability in rat at 10 umol/kg, ip | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 ISSN: 0022-2623 | Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists. |
| AID266265 | Inhibition of ILbeta production in human THP1 cells | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 ISSN: 0022-2623 | Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists. |
| AID266262 | Antagonist activity at human P2X7 receptor expressed in human 1321N1 cells assessed as inhibition of calcium flux by FLIPR | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 ISSN: 0022-2623 | Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists. |
| AID266266 | Reversal of mechanical allodynia in L5/L6 spinal nerve tight ligation model of neuropathic pain in ip dosed rat | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 ISSN: 0022-2623 | Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists. |
| AID1831766 | Displacement of [3H]-A-804598 from human P2X7 receptor expressed in HEK293 cell membrane by in vitro binding assay | 2021 | Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8 ISSN: 1520-4804 | Synthesis and Characterization of the Novel Rodent-Active and CNS-Penetrant P2X7 Receptor Antagonist Lu AF27139. |
| AID1831763 | Antagonist activity at rat P2X7 receptor expressed in HEK293 cells assessed as inhibition of BzATP-induced calcium-flux measured after 60 mins by FLIPR analysis | 2021 | Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8 ISSN: 1520-4804 | Synthesis and Characterization of the Novel Rodent-Active and CNS-Penetrant P2X7 Receptor Antagonist Lu AF27139. |
| AID266264 | Antagonist activity at rat P2X7 receptor expressed in human 1321N1 cells assessed as inhibition of calcium flux by FLIPR | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 ISSN: 0022-2623 | Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists. |
| AID597637 | Antagonist activity at rat recombinant P2X7 receptor expressed in HEK293 cells assessed as inhibition of benzoylbenzoic ATP-induced calcium production by FLIPR assay | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 ISSN: 1464-3405 | Synthesis and in vitro activity of N-benzyl-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine P2X(7) antagonists. |
| AID266263 | Ability to block pore formation in human THP1 cells assessed as inhibition of YO-PRO-1 diiodide dye uptake | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 ISSN: 0022-2623 | Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists. |
| AID760099 | Antagonist activity at P2X7 in Sprague-Dawley rat synaptosome assessed as inhibition of BzATP-induced [3H]D-aspartate efflux preincubated at 10 uM for 8 mins by liquid scintillation counting | 2013 | ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8 ISSN: 1948-5875 | Flow Synthesis and Biological Studies of an Analgesic Adamantane Derivative That Inhibits P2X7-Evoked Glutamate Release. |
| AID597636 | Antagonist activity at human recombinant P2X7 receptor expressed in HEK293 cells assessed as inhibition of benzoylbenzoic ATP-induced calcium production by FLIPR assay | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 ISSN: 1464-3405 | Synthesis and in vitro activity of N-benzyl-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine P2X(7) antagonists. |
| AID423163 | Bioavailability in ip dosed rat | 2009 | Journal of medicinal chemistry, May-28, Volume: 52, Issue:10 ISSN: 1520-4804 | Antagonists of the P2X(7) receptor. From lead identification to drug development. |
| AID266267 | Reversal of mechanical allodynia in L5/L6 spinal nerve tight ligation model of neuropathic pain in ip dosed rat relative to control | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 ISSN: 0022-2623 | Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists. |
| AID321349 | Antagonist activity at human recombinant P2X7 receptor assessed as inhibition of BzATP-induced calcium flux by FLIPR assay | 2008 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6 ISSN: 1464-3405 | Synthesis and in vitro activity of 1-(2,3-dichlorophenyl)-N-(pyridin-3-ylmethyl)-1H-1,2,4-triazol-5-amine and 4-(2,3-dichlorophenyl)-N-(pyridin-3-ylmethyl)-4H-1,2,4-triazol-3-amine P2X7 antagonists. |
| AID423164 | Half life in ip dosed rat | 2009 | Journal of medicinal chemistry, May-28, Volume: 52, Issue:10 ISSN: 1520-4804 | Antagonists of the P2X(7) receptor. From lead identification to drug development. |
| AID1694069 | Antagonist activity at P2X7R in mouse N2a cells assessed as reduction in ATP-induced calcium influx at 5 uM incubated for 1 hr by Fura-2AM dye based spectrofluorometry relative to control | 2021 | Bioorganic & medicinal chemistry, 02-01, Volume: 31ISSN: 1464-3391 | Synthetic 1,4-Naphthoquinones inhibit P2X7 receptors in murine neuroblastoma cells. |
| AID423046 | Activity at rat P2X7 receptor expressed in HEK cells assessed as effect on BzATP-induced ethidium uptake | 2009 | Journal of medicinal chemistry, May-28, Volume: 52, Issue:10 ISSN: 1520-4804 | Antagonists of the P2X(7) receptor. From lead identification to drug development. |
| AID321350 | Antagonist activity at rat recombinant P2X7 receptor assessed as inhibition of BzATP-induced calcium flux by FLIPR assay | 2008 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6 ISSN: 1464-3405 | Synthesis and in vitro activity of 1-(2,3-dichlorophenyl)-N-(pyridin-3-ylmethyl)-1H-1,2,4-triazol-5-amine and 4-(2,3-dichlorophenyl)-N-(pyridin-3-ylmethyl)-4H-1,2,4-triazol-3-amine P2X7 antagonists. |
| AID266270 | Impairment of motor function in rat by rotarod assay up to 300 umol/kg, ip | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 ISSN: 0022-2623 | Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists. |
| AID1358119 | Antagonist activity at human P2X7 receptor in expressed in HEK293 cells assessed as inhibition of BzATP-induced EtBr uptake | 2018 | European journal of medicinal chemistry, May-10, Volume: 151ISSN: 1768-3254 | |
| AID1831762 | Antagonist activity at human P2X7 receptor expressed in HEK293 cells assessed as inhibition of BzATP-induced calcium-flux measured after 60 mins by FLIPR analysis | 2021 | Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8 ISSN: 1520-4804 | Synthesis and Characterization of the Novel Rodent-Active and CNS-Penetrant P2X7 Receptor Antagonist Lu AF27139. |
| AID1831764 | Antagonist activity at mouse P2X7 receptor expressed in HEK293 cells assessed as inhibition of BzATP-induced calcium-flux measured after 60 mins by FLIPR analysis | 2021 | Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8 ISSN: 1520-4804 | Synthesis and Characterization of the Novel Rodent-Active and CNS-Penetrant P2X7 Receptor Antagonist Lu AF27139. |
| AID266269 | Half life in rat at 10 umol/kg | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 ISSN: 0022-2623 | Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists. |
| AID1831769 | Metabolic stability in human liver microsomes assessed as intrinsic clearance at 1 uM incubated for 60 mins by LC-MS/MS analysis | 2021 | Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8 ISSN: 1520-4804 | Synthesis and Characterization of the Novel Rodent-Active and CNS-Penetrant P2X7 Receptor Antagonist Lu AF27139. |
| AID1831770 | Metabolic stability in rat liver microsomes assessed as intrinsic clearance at 1 uM incubated for 60 mins by LC-MS/MS analysis | 2021 | Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8 ISSN: 1520-4804 | Synthesis and Characterization of the Novel Rodent-Active and CNS-Penetrant P2X7 Receptor Antagonist Lu AF27139. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346612 | Human P2X7 (P2X receptors) | 2007 | British journal of pharmacology, Jul, Volume: 151, Issue:5 ISSN: 0007-1188 | Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states. |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 7 (43.75) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (87.50%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3'-o-(4-benzoyl)benzoyladenosine 5'-triphosphate | purine ribonucleoside triphosphate | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | ||
| kn 62 | piperazines | 2009 | 2009 | 15.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 | ||
| az 11645373 | 2009 | 2009 | 15.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 | |||
| az10606120 | 2009 | 2009 | 15.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 | |||
| ce 224,535 | 2021 | 2021 | 3.0 | high | 0 | 0 | 0 | 0 | 0 | 1 | |||
| gsk1482160 | 2021 | 2021 | 3.0 | high | 0 | 0 | 0 | 0 | 0 | 1 | |||
| a-839977 | 2007 | 2007 | 17.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 | |||
| jnj-47965567 | 2021 | 2021 | 3.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ache | 0 | 2006 | 2007 | 17.5 | medium | 0 | 0 | 0 | 2 | 0 | 0 | |
| Arthritis, Rheumatoid | 0 | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Chronic Disease | 0 | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Chronic Illness | 0 | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Congenital Zika Syndrome | 0 | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Disease Models, Animal | 0 | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Inflammation | 0 | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Innate Inflammatory Response | 0 | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Neuroblastoma | 0 | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
| Pain | 0 | 2006 | 2007 | 17.5 | medium | 0 | 0 | 0 | 2 | 0 | 0 | |
| Peripheral Nerve Diseases | 0 | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Peripheral Nervous System Diseases | 0 | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Rheumatoid Arthritis | 0 | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Zika Virus Infection | 0 | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Article | Year |
|---|---|
| Synthesis and Characterization of the Novel Rodent-Active and CNS-Penetrant P2X7 Receptor Antagonist Lu AF27139. Journal of medicinal chemistry, , 04-22, Volume: 64, Issue:8 | 2021 |
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology, , Volume: 96, Issue:5 | 2019 |